Low-dose paclitaxel with immunotherapy for advanced HER2-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Advanced (stage IV) or locally advanced HER2-negative breast cancer confirmed by biopsy
- Previous treatment with 1–4 chemotherapy or targeted therapy regimens for advanced disease
- If hormone-receptor positive: already tried at least one CDK4/6 inhibitor with hormone therapy
- Good overall health (ECOG performance status 0–1) with expected survival of at least 12 weeks
- Normal or near-normal blood counts, liver, and kidney function
- Body surface area between 1.38 m² and 1.87 m² (your doctor will measure this)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental version of the chemotherapy drug paclitaxel for people with advanced breast cancer. It may help shrink tumors and slow the cancer's growth.
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
This trial compares two different chemotherapy combinations (one with a newer type of paclitaxel called polymeric micelles, plus an immunotherapy drug called adebelimab) against a standard taxane plus HP regimen, as first-line treatment for advanced HER2-positive breast cancer. The goal is to see if the new combination works better at controlling the cancer.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.